Patents by Inventor Mark W. Dewhirst
Mark W. Dewhirst has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11786595Abstract: A method and system for treating a subject with a disorder which provides within the subject at least one photoactivatable drug for treatment of the subject, applies initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating at least one photoactivatable drug, and from the CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.Type: GrantFiled: April 12, 2021Date of Patent: October 17, 2023Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Mark Oldham, Justus Adamson, Mark W. Dewhirst, Paul Yoon, Harold Walder, Frederic A. Bourke, Jr., Zakaryae Fathi, Wayne F. Beyer, Jr.
-
Patent number: 11571587Abstract: A method for treating a disease, disorder, or condition in a subject in need thereof, by administering either or both of (i) at least one photoactivatable pharmaceutical agent, or (ii) a first plurality of energy-emitting particles, into the subject in a region of the disease, disorder, or condition, whereby the administering is performed through inhalation; and applying an applied electromagnetic energy to the subject, wherein the applied electromagnetic energy directly or indirectly activates the at least one photoactivatable pharmaceutical agent, when present, and wherein when the first plurality of energy-emitting particles is present, the first plurality of energy-emitting particles absorbs the applied energy and emits an emitted electromagnetic energy, wherein the emitted electromagnetic energy interacts directly with the region of the disease, disorder, or condition or activates the at least one photoactivatable pharmaceutical agent.Type: GrantFiled: April 28, 2020Date of Patent: February 7, 2023Assignees: IMMUNOLIGHT, LLC., DUKE UNIVERSITYInventors: Frederic A. Bourke, Jr., Harold Walder, Zakaryae Fathi, Michael J. Therien, Mark W. Dewhirst, Ian N. Stanton, Jennifer Ann Ayres, Diane Renee Fels, Joseph A. Herbert
-
Publication number: 20220062419Abstract: A method and system for treating a subject with a disorder which provides within the subject at least one photoactivatable drug for treatment of the subject, applies initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating at least one photoactivatable drug, and from the CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.Type: ApplicationFiled: April 12, 2021Publication date: March 3, 2022Applicants: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Mark OLDHAM, Justus ADAMSON, Mark W. DEWHIRST, Paul YOON, Harold WALDER, Frederic A. Bourke, JR., Zakaryae FATHI, Wayne F. BEYER, JR.
-
Patent number: 11135294Abstract: A method and system for treating a subject with a disorder which provides within the subject at least one photoactivatable drug for treatment of the subject, applies initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating at least one photoactivatable drug, and from the CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.Type: GrantFiled: October 26, 2016Date of Patent: October 5, 2021Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Mark Oldham, Justus Adamson, Mark W. Dewhirst, Paul Yoon, Harold Walder, Frederic A. Bourke, Jr., Zakaryae Fathi, Wayne F. Beyer, Jr.
-
Publication number: 20200368547Abstract: A method for treating a disease, disorder, or condition in a subject in need thereof, by administering either or both of (i) at least one photoactivatable pharmaceutical agent, or (ii) a first plurality of energy-emitting particles, into the subject in a region of the disease, disorder, or condition, whereby the administering is performed through inhalation; and applying an applied electromagnetic energy to the subject, wherein the applied electromagnetic energy directly or indirectly activates the at least one photoactivatable pharmaceutical agent, when present, and wherein when the first plurality of energy-emitting particles is present, the first plurality of energy-emitting particles absorbs the applied energy and emits an emitted electromagnetic energy, wherein the emitted electromagnetic energy interacts directly with the region of the disease, disorder, or condition or activates the at least one photoactivatable pharmaceutical agent.Type: ApplicationFiled: April 28, 2020Publication date: November 26, 2020Applicants: IMMUNOLIGHT, LLC., DUKE UNIVERSITYInventors: Frederic A. BOURKE, JR., Harold WALDER, Zakaryae FATHI, Michael J. THERIEN, Mark W. DEWHIRST, Ian N. STANTON, Jennifer Ann AYRES, Diane Renee FELS, Joseph A. HERBERT
-
Patent number: 10709900Abstract: A system and method for light stimulation within a medium. The system has a reduced-voltage x-ray source configured to generate x-rays from a peak applied cathode voltage at or below 105 kVp, and a plurality of energy-emitting particles in the medium which, upon radiation from the x-ray source, radiate at a first lower energy than the x-ray source to interact with least one photoactivatable agent in the medium. The method introduces the plurality of energy-emitting particles into the medium, radiates the energy-emitting particles in the medium with x-rays generated from a peak applied cathode voltage at or below 105 kVp; and emits a lower energy than the x-ray source to interact with the medium or with at least one photoactivatable agent in the medium.Type: GrantFiled: January 18, 2019Date of Patent: July 14, 2020Assignees: IMMUNOLIGHT, LLC., DUKE UNIVERSITYInventors: Frederic A. Bourke, Jr., Harold Walder, Zakaryae Fathi, Michael J. Therien, Mark W. Dewhirst, Ian N. Stanton, Jennifer Ann Ayres, Diane Renee Fels, Joseph A. Herbert
-
Patent number: 10596387Abstract: A system and method for imaging or treating a disease in a human or animal body. The system provides to the human or animal body a pharmaceutical carrier including one or more phosphors which are capable of emitting ultraviolet or visible light into the body and which provide x-ray contrast. The system includes one or more devices which infuse a diseased site with a photoactivatable drug and the pharmaceutical carrier, an initiation energy source comprising an x-ray or high energy source which irradiates the diseased site with at least one of x-rays, gamma rays, or electrons to thereby initiate emission of said ultraviolet or visible light into the body, and a processor programmed to at least one of 1) produce images of the diseased site or 2) control a dose of said x-rays, gamma rays, or electrons to the diseased site for production of said ultraviolet or visible light at the diseased site to activate the photoactivatable drug.Type: GrantFiled: April 22, 2015Date of Patent: March 24, 2020Assignees: IMMUNOLIGHT, LLC., DUKE UNIVERSITYInventors: Harold Walder, Frederic A. Bourke, Zakaryae Fathi, Wayne F. Beyer, Mark W. Dewhirst, Mark Oldham, Justus Adamson, Michael Nolan
-
Publication number: 20190168015Abstract: A system and method for light stimulation within a medium. The system has a reduced-voltage x-ray source configured to generate x-rays from a peak applied cathode voltage at or below 105 kVp, and a plurality of energy-emitting particles in the medium which, upon radiation from the x-ray source, radiate at a first lower energy than the x-ray source to interact witht least one photoactivatable agent in the medium. The method introduces the plurality of energy-emitting particles into the medium, radiates the energy-emitting particles in the medium with x-rays generated from a peak applied cathode voltage at or below 105 kVp; and emits a lower energy than the x-ray source to interact with the medium or with at least one photoactivatable agent in the medium.Type: ApplicationFiled: January 18, 2019Publication date: June 6, 2019Applicants: IMMUNOLIGHT, LLC., DUKE UNIVERSITYInventors: Frederic A. BOURKE, JR., Harold Walder, Zakaryae Fathi, Michael J. Therien, Mark W. Dewhirst, Ian N. Stanton, Jennifer Ann Ayres, Diane Renee Fels, Joseph A. Herbert
-
Patent number: 10232190Abstract: A system and method for light stimulation within a medium. The system has a reduced-voltage x-ray source configured to generate x-rays from a peak applied cathode voltage at or below 105 kVp, and a plurality of energy-emitting particles in the medium which, upon radiation from the x-ray source, radiate at a first lower energy than the x-ray source to interact with at least one photoactivatable agent in the medium. The method introduces the plurality of energy-emitting particles into the medium, radiates the energy-emitting particles in the medium with x-rays generated from a peak applied cathode voltage at or below 105 kVp; and emits a lower energy than the x-ray source to interact with the medium or with at least one photoactivatable agent in the medium.Type: GrantFiled: July 14, 2017Date of Patent: March 19, 2019Assignees: IMMUNOLIGHT, LLC., DUKE UNIVERSITYInventors: Frederic A. Bourke, Jr., Harold Walder, Zakaryae Fathi, Michael J. Therien, Mark W. Dewhirst, Ian N. Stanton, Jennifer Ann Ayres, Diane Renee Fels, Joseph A. Herbert
-
Publication number: 20180311355Abstract: A method and system for treating a subject with a disorder which provides within the subject at least one photoactivatable drug for treatment of the subject, applies initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating at least one photoactivatable drug, and from the CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.Type: ApplicationFiled: October 26, 2016Publication date: November 1, 2018Inventors: Mark OLDHAM, Justus ADAMSON, Mark W. DEWHIRST, Paul YOON, Harold WALDER, Frederic A. BOURKE, Zakaryae FATHI, Wayne F. BEYER
-
Patent number: 9907976Abstract: A system and method for light stimulation within a medium. The system has a reduced-voltage x-ray source configured to generate x-rays from a peak applied cathode voltage at or below 105 kVp, and a plurality of energy-emitting particles in the medium which, upon radiation from the x-ray source, radiate at a first lower energy than the x-ray source to interact with at least one photoactivatable agent in the medium. The method introduces the plurality of energy-emitting particles into the medium, radiates the energy-emitting particles in the medium with x-rays generated from a peak applied cathode voltage at or below 105 kVp; and emits a lower energy than the x-ray source to interact with the medium or with at least one photoactivatable agent in the medium.Type: GrantFiled: July 9, 2012Date of Patent: March 6, 2018Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Frederic A. Bourke, Jr., Harold Walder, Zakaryae Fathi, Michael J. Therien, Mark W. Dewhirst, Ian N. Stanton, Jennifer Ann Ayres, Diane Renee Fels, Joseph A. Herbert
-
Publication number: 20170319868Abstract: A system and method for light stimulation within a medium. The system has a reduced-voltage x-ray source configured to generate x-rays from a peak applied cathode voltage at or below 105 kVp, and a plurality of energy-emitting particles in the medium which, upon radiation from the x-ray source, radiate at a first lower energy than the x-ray source to interact with at least one photoactivatable agent in the medium. The method introduces the plurality of energy-emitting particles into the medium, radiates the energy-emitting particles in the medium with x-rays generated from a peak applied cathode voltage at or below 105 kVp; and emits a lower energy than the x-ray source to interact with the medium or with at least one photoactivatable agent in the medium.Type: ApplicationFiled: July 14, 2017Publication date: November 9, 2017Applicants: IMMUNOLIGHT, LLC., DUKE UNIVERSITYInventors: Frederic A. Bourke, JR., Harold Walder, Zakaryae Fathi, Michael J. Therien, Mark W. Dewhirst, Ian N. Stanton, Jennifer Ann Ayres, Diane Renee Fels, Joseph A. Herbert
-
Publication number: 20170283882Abstract: This disclosure provides methods and compositions of matter relating to the monitoring of relative concentrations of pairs of isoforms of mRNA or downstream expression products thereof. The methods can include measuring a relative expression level of a pair of mRNA isoforms or downstream expression products thereof and comparing the relative expression level to relative historical or cohort expression levels of the same pair of mRNA isoforms. The result of the comparison can lead to a more accurate prognosis for the subject.Type: ApplicationFiled: September 8, 2015Publication date: October 5, 2017Inventors: Timothy J. Robinson, Mark W. Dewhirst
-
Patent number: 9709551Abstract: The present invention relates to the innovation that ECFCs are a predictor of the likely result to the exposure of a patient to low dose ionizing radiation by comparing the results of exposure of cells to individuals already exposed to ECFCs.Type: GrantFiled: January 28, 2014Date of Patent: July 18, 2017Assignee: Creative Scientist, Inc.Inventors: Alexander V Kinev, Dora Il'yasova, Mark W. Dewhirst
-
Publication number: 20170115293Abstract: Methods for predicting the radiosensitivity of a cancer tumor and treating cancer in a subject are provided. In another aspect, methods of treating cancer in a subject are also provided. The methods may include administering to the subject radiation therapy based on the expression level of no more than 35, 30, 25, 20, 15, 10, or 5 biomarkers in a tumor sample from the subject. The methods of treating cancer in a subject may also include administering a therapeutically effective amount of a FAS agonist and/or a TNFRSF10B agonist to the subject, and administering radiation therapy to the subject.Type: ApplicationFiled: October 21, 2016Publication date: April 27, 2017Applicant: DUKE UNIVERSITYInventors: Janet Horton, Jen-Tsan Ashley Chi, Sharareh Reihani, Mark W. Dewhirst
-
Publication number: 20170050046Abstract: A system and method for imaging or treating a disease in a human or animal body. The system provides to the human or animal body a pharmaceutical carrier including one or more phosphors which are capable of emitting ultraviolet or visible light into the body and which provide x-ray contrast. The system includes one or more devices which infuse a diseased site with a photo-activatable drug and the pharmaceutical carrier, an initiation energy source comprising an x-ray or high energy source which irradiates the diseased site with at least one of x-rays, gamma rays, or electrons to thereby initiate emission of said ultraviolet or visible light into the body, and a processor programmed to at least one of 1) produce images of the diseased site or 2) control a dose of said x-rays, gamma rays, or electrons to the diseased site for production of said ultraviolet or visible light at the diseased site to activate the photoactivatable drug.Type: ApplicationFiled: April 22, 2015Publication date: February 23, 2017Applicants: IMMUNOLIGHT, LLC., DUKE UNIVERSITY, NORTH CAROLINA STATE UNIVERSITYInventors: Harold WALDER, Frederic A. BOURKE, Zakaryae FATHI, Wayne F. BEYER, Mark W. DEWHIRST, Mark OLDHAM, Justus ADAMSON, Michael NOLAN
-
Publication number: 20150355164Abstract: The present invention relates to the innovation that ECFCs are a predictor of the likely result to the exposure of a patient to low dose ionizing radiation by comparing the results of exposure of cells to individuals already exposed to ECFCs.Type: ApplicationFiled: January 28, 2014Publication date: December 10, 2015Applicant: CREATIVE SCIENTIST, LLCInventors: Alexander V Kinev, Dora Il'yasova, Mark W. Dewhirst
-
Patent number: 9056080Abstract: The presently disclosed subject matter provides methods for increasing perfusion in hypoxic regions of tissues in subjects. Also provided are methods for treating diseases and/or disorders associated with hypoxia in subjects, methods for increasing sensitivity of tumors to radiation and/or chemotherapy treatments, methods for delaying tumor growth in subjects, and methods for inhibiting tumor blood vessel growth in subjects. In some embodiments, the presently disclosed methods involve administering to subjects in need thereof a first composition selected from the group consisting of a nitrosylated hemoglobin and an agent that induces nitrosylation of endogenous hemoglobin in the subject and a second composition comprising a hyperoxic gas. In some embodiments, the presently disclosed methods also include treating a tumor with radiation therapy, chemotherapy, photodynamic therapy, immunotherapy, or combinations thereof. Also provided are inhalable gases that can be employed in the presently disclosed methods.Type: GrantFiled: June 17, 2013Date of Patent: June 16, 2015Assignee: Duke UniversityInventors: Mark W. Dewhirst, Jonathan S. Stamler, Timothy J. McMahon, Pierre D. Sonveaux
-
Patent number: 8968702Abstract: The presently disclosed subject matter generally relates to methods and compositions for inhibiting the expression and/or activation of hypoxia-inducible factor 1 (HIF-1) genes in a hypoxic cell. More particularly, the methods disclosed herein relate to inhibition of HIF-1 activation in a cell, increasing sensitivity of a tumor cell to radiation and/or chemotherapy, delaying tumor growth, inhibiting tumor blood vessel growth, inhibiting inflammatory responses in a cell through the use of compositions that prevent the nitrosylation of HIF-1, and methods for screening for new inhibitors of HIF-1 activiation. Additionally, the compositions disclosed herein relate to compositions that can be employed in, and are identified by, the disclosed methods.Type: GrantFiled: March 30, 2007Date of Patent: March 3, 2015Assignee: Duke UniversityInventors: Chuan-Yuan Li, Fang Li, Pierre Sonveaux, Mark W. Dewhirst
-
Publication number: 20140323946Abstract: A system and method for light stimulation within a medium. The system has a reduced-voltage x-ray source configured to generate x-rays from a peak applied cathode voltage at or below 105 kVp, and a plurality of energy-emitting particles in the medium which, upon radiation from the x-ray source, radiate at a first lower energy than the x-ray source to interact with at least one photoactivatable agent in the medium. The method introduces the plurality of energy-emitting particles into the medium, radiates the energy-emitting particles in the medium with x-rays generated from a peak applied cathode voltage at or below 105 kVp; and emits a lower energy than the x-ray source to interact with the medium or with at least one photoactivatable agent in the medium.Type: ApplicationFiled: July 9, 2012Publication date: October 30, 2014Applicants: DUKE UNIVERSITY, IMMUNOLIGHT, LLCInventors: Frederic A. Bourke, JR., Harold Walder, Zakaryae Fathi, Michael J. Therien, Mark W. Dewhirst, Ian N. Stanton, Jennifer Ann Ayres, Diane Renee Fels, Joseph A. Herbert